Choice and use of newer anticonvulsant drugs in older patients

Drugs and Aging

Volumn 17, Issue 6, 2000, Pages 441-452

  Willmore, L James ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; GLUTAMIC ACID; LAMOTRIGINE; NEW DRUG; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

AGED; AGING; APLASTIC ANEMIA; BODY COMPOSITION; CONVULSION; DROWSINESS; DRUG ABSORPTION; DRUG CHOICE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PROTEIN BINDING; HEADACHE; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; NEPHROLITHIASIS; POLYPHARMACY; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT PLANNING; VISUAL DISORDER;

EID: 0034486307     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200017060-00002     Document Type: Review

References (73)

1. Clinical pharmacology of new antiepileptic drugs
2. Seizure disorders: The changes with age
3. How common are epileptic seizures in old age
4. Late onset epilepsy: Etiologies, types of seizures, and value of clinical investigation, EEG and computerized tomography scan
5. Etiology of seizures in the elderly
6. A survey of epileptic disorders in southwest France: Seizures in elderly patients
7. Anticonvulsant therapy in the elderly: A need for placebo controlled trials
8. Importance of protein binding for the interpretation of serum or plasma drug concentrations
9. Protein binding drug displacement interactions
10. Clinical pharmacology of antiepileptic drugs in the elderly: Practical applications
11. Commonly used antiepileptic drugs: Age-related pharmacokinetics
12. The effect of age upon liver volume and apparent liver blood flow in healthy man
13. Age-related changes in liver size and hepatic blood flow: The influence on drug metabolism in the elderly
14. Drug metabolism in the elderly
15. Effect of age and sex on the plasma binding of acidic and basic drugs
16. Antiepileptic drugs and alpha-1 acid glyeoprotein
17. Increased sensitivity to nitrazepam in old age
18. Measured versus estimated creatinine clearance in a high-functioning elderly sample: MacArthur Foundation Study of Successful Aging
19. Antiepileptic drugs in the elderly
20. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy
21. Interference of oral phenytoin absorption by continuous nasogastric feeding
22. Aging, total body potassium, fat free mass and cell mass in males and females between the ages of 18 and 85 years
23. Long v short half-life benzodiazepines in the elderly
24. Antiepileptic drugs in the elderly: Pharmacoepidemiology and pharmacokinetics
25. Metabolism of antiepileptic medication: Newborn to elderly
26. Effect of felbamate on phenytoin and carbamazepine serum concentrations
27. Felbamate: A clinical trial for complex partial seizures
28. Open pilot study of felbamate (ADD 03055) in partial seizures
29. Gabapentin
30. Double-blind study of gabapentin in the treatment of partial seizures
31. Gabapentin as an antiepileptic drug in man
32. Gabapentin as add-on therapy in refractory partial epilepsy
33. Gabapentin in partial epilepsy
34. Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study
35. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma
36. Gabapentin
37. Clinical pharmacokinetics of gabapentin
38. Voltage-activated calcium channels: Targets of antiepileptic drug therapy?
39. Lamotrigine therapy for partial seizures: A multicenter placebo-controlled, double-blind, crossover trial
40. Adult experience with lamotrigine
41. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
42. Lamotrigine substitution study: Evidence for synergism with sodium valproate
43. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy
44. Lamotrigine
45. Lamotrigine versus carbamazepine: A double-blind comparative study in newly diagnosed epilepsy
46. Lamotrigine: A review of its pharmacological properties and clinical efficacy in epilepsy
47. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers
48. The influence of age on the antiepileptic agent oxcarbazepine
49. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment
50. Oxcarbazepine: A double-blind, placebo-controlled, monotherapy trial for partial seizures
51. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy
52. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy
53. A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy
54. Hyponatraemia during oxcarbazepine therapy
55. Oxcarbazepine (GP47.680): A possible alternative to carbamazepine
56. Hyponatremia induced by oxcarbazepine
57. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy
58. Double-blind, placebo-controlled trial of topiramate (600mg daily) for the treatment of refractory partial epilepsy
59. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures
60. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages
61. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages
62. Progress report on new antiepileptic drugs a summary of the second Eilat conference
63. (R)-N-[4,4-bis(3-methyl-7-thienyl) but-3-en-1-yl] Nipecotic acid binds with high affinity to the brain gamma (symbol)-aminobutyric acid uptake carrier
64. Tiagabine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy
65. The clinical pharmacokinetics of the newer antiepileptic drugs
66. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy
67. Tiagabine
68. Pharmacokinetics of vigabatrin: Implications of creatinine clearance
69. Vigabatrin
70. Vigabatrin-associated retinal cone system dysfunction
71. Efficacy and safety of zonisamide: Results of a multicenter study
72. Advanced Alzheimer's disease is a risk factor for late-onset seizures